Hospital Mandatory Reporting in Three Stages: What Hospitals Must Report from 21 March 2026

1. Key takeaways

The reading that “from March 2026 hospitals must report everything” is a misinterpretation. What becomes mandatory from 21 March 2026 is only the category of death or serious deterioration in health, and the device scope is limited to Class III devices and Class 4 IVDs. Near adverse events do not become mandatory until 1 April 2028 (Stage 2), and events connected with a “treatment” must wait until 1 April 2030 (Stage 3). The staged design means the reporting scope widens at each stage: a sponsor whose products sit outside Class III and Class 4 IVDs still has obligations coming, only on a later timetable, so the scope at each stage matters as much as the dates. For hospital-facing portfolios, the voluntary period that preceded 21 March 2026 should be treated as the rehearsal window in which reporting workflows were meant to be tested.

2. Legal basis

The hospital reporting regime is built from a 2023 amendment Act, a 2025 consequential regulation, and a staged timetable administered through a dedicated reporting system and an accreditation advisory. Because the reporting duty falls on the facilities themselves rather than on sponsors, the sponsor’s exposure is indirect but real: the devices being reported are the sponsor’s own.

1. Primary legislation: Therapeutic Goods Amendment (2022 Measures No. 1) Act 2023, legal number No. 10, 2023, registered as C2023A00010, Schedule 1.
2. Consequential regulations: Therapeutic Goods Legislation Amendment (Australian Unique Device Identification Database and Other Measures) Regulations 2025 (F2025L00414), in force March 2025 (expressed by ACSQHC as 21 March 2025).
3. Timetable: voluntary reporting period 21 March 2025 — 20 March 2026; mandatory start date 21 March 2026; the responsible person is the facility’s CEO (however described).
4. Facilities covered: public hospitals, private hospitals and day hospital facilities (as defined in section 121-5(5) and 121-5(8) of the Private Health Insurance Act 2007); the regime does not apply to general practice clinics or residential aged care facilities.
5. Reporting deadlines: death or serious deterioration 10 days; near adverse events and treatment-related events 45 days (running from the day of the intervention or the day the treatment was provided; the TGA recommends batch submission on the first working day of each month).
6. Three stages: Stage 1 (21 March 2026 — 31 March 2028; Class III and Class 4 IVD); Stage 2 (1 April 2028 — 31 March 2030; extended to Class IIa, IIb and III devices and Class 3 and 4 IVDs, and covering near adverse events); Stage 3 (from 1 April 2030; covering “treatment”).
7. Dedicated system: ASDER (Adverse Signal Detection and Event Reporting); hospitals and central reporting entities must register before reporting.
8. Accreditation link: ACSQHC Advisory AS25/01 (v1.0, published December 2025, review December 2027) — linked to NSQHS Standard Action 1.11; from 21 March 2026, assessors will rate this action as “Met” for facilities that have established a compliant reporting system.
9. [Practical estimate] The claim that accreditation standards apply from 2030 has no official source; in AS25/01 the year 2030 corresponds to the expansion of the reporting scope (treatment included from 1 April 2030), while the accreditation linkage is assessed from March 2026.

3. Expert insights

Insight 1: the sponsor’s data upstream has changed. Once hospitals report directly to the TGA, the sponsor is no longer the only reporting source. The same event may be reported separately by the hospital and by the sponsor, and inconsistent accounts between the two sides will invite TGA follow-up questions. Sponsors need event notification agreements with their key hospital customers. A short written protocol covering what will be notified, by whom and within what period is usually enough to keep the two accounts from diverging.

Insight 2: 2030 is a scope extension point, not the start of accreditation. The ACSQHC assessment takes effect from 21 March 2026. Writing 2030 as the point from which accreditation standards apply will cause companies to misjudge their preparation timeline. The assessment linkage and the scope extension are two separate clocks, and the compliance calendar should be designed against both.

Insight 3: the scope expressly excludes general practice clinics and aged care facilities. Products aimed at primary care clinics will not see additional data flowing back from hospital direct reporting in the short term; products aimed at high-value hospital consumables and Class 4 IVDs will see a significant increase in returning data. For sponsors, the practical consequence is that portfolio mix — not company size — determines how much new data flow to expect once hospital reporting becomes mandatory. The split also matters for feedback channels, because input from primary-care settings will not arrive through hospital reporting at all.

4. Practical recommendations

• Classify Class III and Class 4 IVD products as the first priority group, and verify that the vigilance system can complete a report consistent with the hospital’s account within 10 days, including the case detail needed to reconcile the two records. That check should be part of the periodic vigilance review rather than an ad-hoc exercise.
• Establish event notification agreements with major hospital customers, agreeing on an information synchronisation mechanism before either party submits a report, so that both filings rest on the same facts.
• Plan backwards from Stage 2 (1 April 2028) and Stage 3 (1 April 2030), and bring Class IIa and IIb devices and Class 3 IVDs into the next batch of preparation, so that labelling and vigilance changes land before each stage boundary rather than after it.
• Monitor the review of ACSQHC Advisory AS25/01 due in December 2027, and adjust the accreditation preparation plan according to its outcome.

5. Verification checklist

• □ Confirmed that Stage 1 covers Class III and Class 4 IVD with a 10-day deadline
• □ Confirmed that the scope excludes general practice clinics and aged care facilities
• □ Event notification agreements have been established with major hospital customers
• □ Preparation for the next batch has been planned backwards from 1 April 2028 and 1 April 2030
• □ The review of AS25/01 in December 2027 is being monitored

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Australian market. Our team manages adverse event reporting and recall coordination with the TGA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com